- Home
- ADPT vs TDC Comparison
ADPT vs TDC Comparison
Compare ADPT & TDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADPT | TDC |
|---|---|---|
| Founded | 2009 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ADPT | TDC |
|---|---|---|
| Price | $13.56 | $32.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $17.78 | ★ $34.78 |
| AVG Volume (30 Days) | 1.6M | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | 16.38 |
| EPS | N/A | ★ 3.47 |
| Revenue | $276,976,000.00 | ★ $2,156,000,000.00 |
| Revenue This Year | $3.98 | $0.30 |
| Revenue Next Year | $22.72 | $1.44 |
| P/E Ratio | ★ N/A | $9.05 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $8.50 | $19.83 |
| 52 Week High | $20.76 | $41.78 |
Technical Indicators
Market Signals| Indicator | ADPT | TDC |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 72.52 |
| Support Level | $12.22 | $28.98 |
| Resistance Level | $15.38 | $41.78 |
| Average True Range (ATR) | 0.79 | 1.55 |
| MACD | -0.02 | 0.59 |
| Stochastic Oscillator | 27.88 | 96.18 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.